INFINITY Angioplasty Balloon Catheter™ Receives 510(k) Clearance: Game Changing Innovation in Percutaneous Angioplasty Balloon Design and Utility

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

June 16, 2020

INFINITY Angioplasty Balloon Catheter has been cleared by the FDA for PTA treatment of peripheral arterial disease, in peripheral vasculature including iliac, femoral, popliteal, infra-popliteal arteries and for the treatment of AV dialysis fistulae.

“The INFINITY catheter represents a game-changing innovation in percutaneous angioplasty balloon design and utility,” states founder and vascular surgeon, John Pigott, MD. “A single SKU to treat lesions from 40mm-250mm in length, is adjustable, to the millimeter, in vivo assuring Precision Angioplasty™, while addressing over 95 percent of real-life clinical cases.”

“Adopting the INFINITY platform reduces inventory needs and costs from dozens of SKU’s to two, it reduces space requirements, inventory management time, and trunk stock, while delivering the assurance that the right balloon size will always be on the shelf – INFINITY is a highly differentiated product” – reports CEO Gary Smith.  “This is an ideal product for both Office-Based Labs and Hospitals.”  While initially launching an uncoated angioplasty balloon, the Company intends to follow quickly with a DCB platform of a similar design – protected balloon will assure precise delivery of drug to the lesion site.

Key investors include ProMedica Innovations, Northwest Ohio Tech Fund II, and the Global Cardiovascular Innovation Center.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine

Related Articles